News
Bavarian Nordic bags $22.5M Canadian vaccine order
The order will cover the manufacturing of bulk vaccine in 2026
- By IPP Bureau
| February 23, 2026
Vax major Bavarian Nordic has landed a USD 22.5 million order from the Public Health Agency of Canada (PHAC) for its mpox and smallpox vaccine, MVA-BN.
The order, placed under a 10-year contract framework established in 2022, will cover the manufacturing of bulk vaccine in 2026, with final drug product filling and delivery scheduled for later.
With this latest award, Bavarian Nordic’s Public Preparedness business for 2026 has now reached approximately DKK 1,400 million in orders—up DKK 100 million from the company’s previous update. Full-year guidance for this segment remains unchanged at DKK 1,800–2,000 million.
“Public preparedness has remained a high priority in Canada for years, and we are proud to continue to support the government’s commitment to protecting its citizens against serious health threats, like mpox and smallpox,” said Paul Chaplin, President & CEO of Bavarian Nordic.
“It is our aim to build and strengthen collaborations like this, as we have also done for decades with the US government through BARDA, and more recently with the EU through HERA, to facilitate a stronger public health response as a critical part of the defense against viral threats globally.”
